News FDA approves expanded use for GSK's COPD triple therapy GSK is aiming to revive its respiratory drugs franchise
Partner Content Partner Content SMi's Asthma & COPD conference next week in London SMi Group reports: Limited availability on Managers Special Discount
Market Access Verona to take COPD hopeful into phase 3 Verona Pharma is to take lung drug RPL554 into late clinical development after a successful phase 2b trial.
News AZ boosted by COPD triple inhaler results AstraZeneca may mount a challenge to GlaxoSmithKline’s three-in-one inhaler for chronic obstructive pulmonary disease (COPD) after a late-stage trial success.
News Rumours of $1.65bn GSK bid for respiratory partners Vectura GlaxoSmithKline could be poised to acquire its respiratory partner, UK biotech Vectura, for $1.65bn.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.